Your browser is no longer supported. Please, upgrade your browser.
ACRX AcelRx Pharmaceuticals, Inc. monthly Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own2.20% Shs Outstand82.67M Perf Week-17.32%
Market Cap86.80M Forward P/E- EPS next Y-0.27 Insider Trans1.87% Shs Float71.42M Perf Month-23.36%
Income-53.20M PEG- EPS next Q-0.16 Inst Own24.00% Short Float15.88% Perf Quarter-48.53%
Sales2.30M P/S37.74 EPS this Y16.70% Inst Trans- Short Ratio11.81 Perf Half Y-51.61%
Book/sh-0.52 P/B- EPS next Y46.00% ROA-50.10% Target Price5.80 Perf Year-69.30%
Cash/sh0.80 P/C1.31 EPS next 5Y- ROE221.80% 52W Range0.70 - 4.00 Perf YTD-50.24%
Dividend- P/FCF- EPS past 5Y2.60% ROI340.90% 52W High-73.75% Beta1.66
Dividend %- Quick Ratio5.00 Sales past 5Y-15.20% Gross Margin- 52W Low49.70% ATR0.16
Employees99 Current Ratio5.30 Sales Q/Q-16.70% Oper. Margin- RSI (14)43.95 Volatility9.36% 16.22%
OptionableYes Debt/Eq- EPS Q/Q-2.10% Profit Margin- Rel Volume0.53 Prev Close1.08
ShortableYes LT Debt/Eq- EarningsMar 16 BMO Payout- Avg Volume960.26K Price1.05
Recom1.80 SMA20-3.33% SMA50-24.22% SMA200-47.90% Volume511,243 Change-2.78%
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Apr-02-20 12:28PM  The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore Zacks
Apr-01-20 10:22AM  Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT Thomson Reuters StreetEvents -12.71%
08:18AM  After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys Zacks
Mar-27-20 12:00PM  All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy Zacks
Mar-18-20 06:05AM  AcelRx Pharmaceuticals, Inc. Just Reported, And Analysts Assigned A US$6.40 Price Target Simply Wall St. -12.64%
Mar-17-20 05:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tetraphase Pharmaceuticals, Inc. with AcelRx Pharmaceuticals, Inc. is Fair to TTPH Shareholders ACCESSWIRE +13.49%
01:47PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Tetraphase Pharmaceuticals, Inc. PR Newswire
Mar-16-20 05:10PM  TETRAPHASE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger ACCESSWIRE -18.46%
09:02AM  AcelRx Pharmaceuticals: Q4 Earnings Insights Benzinga
07:35AM  AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results PR Newswire
07:30AM  AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals PR Newswire
Mar-11-20 07:50PM  AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020 PR Newswire
Mar-10-20 02:25PM  AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April PR Newswire
Mar-06-20 11:55AM  AcelRx Announces Agreement for an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Spine Surgery PR Newswire
Feb-27-20 12:30PM  Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q4 Earnings Expected to Decline Zacks
Feb-24-20 10:28AM  AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-07-20 06:49AM  Should You Worry About AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Salary Level? Simply Wall St.
Jan-27-20 05:45PM  AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know Zacks
Jan-13-20 05:50PM  AcelRx Pharmaceuticals (ACRX) Stock Sinks As Market Gains: What You Should Know Zacks
07:00AM  AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates PR Newswire
Jan-07-20 10:21AM  Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study Zacks
09:51AM  Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA Zacks
09:17AM  Catalyst Gives Preliminary Firdapse Estimates & Other Updates Zacks
Jan-06-20 06:38AM  Have Faith in Rising P/E: Play 5 Top-Ranked Stocks Zacks
Jan-03-20 12:00PM  AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
09:07AM  Top Ranked Momentum Stocks to Buy for January 3rd Zacks
Dec-31-19 11:05AM  Jazz Enrolls First Patient in Phase II/III Leukemia Study Zacks
Dec-30-19 05:21AM  How Much Are AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Insiders Spending On Buying Shares? Simply Wall St. -5.36%
Dec-20-19 05:46PM  Is AcelRx Pharmaceuticals Inc (ACRX) A Good Stock To Buy? Insider Monkey
Dec-13-19 08:39AM  Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M Zacks
Nov-13-19 09:24AM  AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
07:00AM  AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets PR Newswire
05:04AM  AcelRx Pharmaceuticals Enters Oversold Territory Zacks
Nov-12-19 05:40AM  Edited Transcript of ACRX earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-11-19 05:15AM  AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Is Breakeven Near? Simply Wall St. -8.25%
Nov-06-19 07:25PM  AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates Zacks -5.91%
04:05PM  AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results PR Newswire
Nov-05-19 04:05PM  AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference PR Newswire
Oct-30-19 10:33AM  Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline Zacks -6.48%
Oct-28-19 04:30PM  AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019 PR Newswire
Oct-25-19 10:30AM  Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline Zacks
Oct-23-19 09:00AM  AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade Zacks
Oct-16-19 07:00AM  Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists PR Newswire
Aug-30-19 09:49AM  Why this biotech's new-school opioid is on hold with the FDA American City Business Journals
Aug-15-19 04:05PM  AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium PR Newswire
Aug-12-19 07:48AM  Edited Transcript of ACRX earnings conference call or presentation 5-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-05-19 09:24PM  AcelRx Pharmaceuticals Inc (ACRX) Q2 2019 Earnings Call Transcript Motley Fool
05:35PM  AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM  AcelRx Pharmaceuticals Reports Second Quarter 2019 Financial Results PR Newswire
Aug-02-19 10:12AM  AcelRx to announce second quarter 2019 results and provide an update on the company's business on Monday, August 5th, 2019 PR Newswire -5.10%
Jul-25-19 10:33AM  Analysts Estimate AcelRx Pharmaceuticals (ACRX) to Report a Decline in Earnings: What to Look Out for Zacks
07:29AM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
Jul-01-19 02:00PM  AcelRx added to the Russell 2000® and 3000® indexes PR Newswire
Jun-28-19 06:53PM  Hedge Funds Have Never Been More Bullish On AcelRx Pharmaceuticals Inc (ACRX) Insider Monkey +20.48%
Jun-13-19 05:05PM  Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks
Jun-06-19 08:26PM  Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents +7.36%
Jun-03-19 07:00AM  AcelRx announces the closing of a $25 million senior secured debt facility PR Newswire -5.41%
May-17-19 09:00AM  AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why Zacks
May-09-19 03:21PM  AcelRx Pharmaceuticals Inc (ACRX) Q1 2019 Earnings Call Transcript Motley Fool -9.40%
12:48PM  Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today Motley Fool
May-08-19 06:15PM  AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:09PM  AcelRx Pharmaceuticals: 1Q Earnings Snapshot Associated Press
02:30PM  AcelRx Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-07-19 04:48PM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks
May-01-19 10:33AM  Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-29-19 11:29AM  3 Stocks Peter Lynch Would Love Motley Fool
Apr-25-19 04:05PM  AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019 PR Newswire
Apr-20-19 09:06AM  Penny Stocks to Buy Using Technical Analysis for April 2019 Investopedia
Apr-11-19 04:37PM  AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting PR Newswire
Apr-09-19 11:05AM  Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Apr-03-19 09:16AM  Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy Zacks
Mar-28-19 09:00AM  AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-11-19 04:01PM  AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference PR Newswire -6.12%
Mar-08-19 12:03PM  Why AcelRx Pharmaceuticals Stock Is Sinking Today Motley Fool -13.03%
10:00AM  Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX) Zacks
Mar-07-19 04:01PM  AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Mar-04-19 10:43AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Feb-22-19 09:25AM  AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019 PR Newswire
Feb-19-19 10:00AM  Biotech Leaders to Watch This Week ACCESSWIRE +9.31%
09:35AM  4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19) ACCESSWIRE
Feb-11-19 09:30AM  Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year? Zacks
Jan-31-19 07:00AM  AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium PR Newswire
Jan-09-19 07:20AM  Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services Discovering Underlying Factors of Influence GlobeNewswire
Jan-07-19 08:30AM  AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain PR Newswire
Dec-27-18 09:23AM  2 Biotech Penny Stocks to Buy Right Now Motley Fool +7.31%
Dec-23-18 09:25PM  Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX) Insider Monkey
Dec-21-18 08:51AM  Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options Zacks
Dec-18-18 07:00AM  AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI) PR Newswire -5.56%
Dec-01-18 08:30AM  3 Stocks to Hold for the Next 20 Years Motley Fool
Nov-29-18 04:35PM  AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11 PR Newswire
Nov-21-18 09:25AM  New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE
Nov-19-18 05:53PM  Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 04:05PM  AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting PR Newswire -5.06%
Nov-09-18 01:43PM  Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today Motley Fool -16.11%
09:10AM  AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
07:35AM  Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM  AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Nov-07-18 05:19PM  AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference PR Newswire -8.97%
Nov-06-18 07:44AM  Powerful new opioid 500 times stronger than morphine approved in U.S. in spite of outcry MarketWatch -8.67%
Nov-05-18 05:38PM  Health Care Digest: Health's push onto the ballot, an exec's cancer story and more American City Business Journals -11.04%
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EDWARDS MARK GDirectorNov 12Buy1.7825,00044,575243,750Nov 12 04:22 PM
Angotti Vincent J.Chief Executive OfficerNov 11Buy1.798,37914,973275,944Nov 12 06:07 AM
EDWARDS MARK GDirectorAug 26Buy2.175,00010,850218,750Aug 26 04:52 PM
EDWARDS MARK GDirectorAug 23Buy2.2010,00021,956213,750Aug 26 04:52 PM
Angotti Vincent J.Chief Executive OfficerJun 05Buy2.315,00011,550262,884Jun 06 06:02 AM